Table 3.
Identification of key MMD-associated target genes
| Proteins | Enriched p value | Function | ProtoArray p value | DER * | Chromosomal location |
|---|---|---|---|---|---|
| APP |
< 0.02 |
Increased risk of hemorrhagic stroke, Alzheimer disease pathogenesis, DDR [40-42] |
0.029 |
0.604 |
21q21.3 |
| CTNNB1 |
0.01 |
Regulation of neural progenitor cell cycle, Wnt signaling in carcinoma/angiogenesis, chromosome instability [43-45] |
0.0197 |
0.555 |
3p21 |
| EDIL3 |
0.01 |
Role in angiogenesis and vessel wall remodeling and development [46,47] |
0.0003 |
0.484 |
5q14 |
| ROR1 |
0.01 |
Possible role in cell migration and remodeling of cytoskeleton [48] |
0.0029 |
0.586 |
1p32-p31 |
| GPS1 |
0.02 |
Component of the COP9 signalosome, DDR [49] |
0.07 |
0.46 |
17q25.3 |
| STRA13 | 0.01 | Component of the FA protein complex, DDR, component of the kinetocore [50-52] | 0.0021 | 0.581 | 17q25.3 |
MMD-specific target proteins were identified through functional interpolating SNPs approach (fitSNPs), a bioinformatics method that integrates antibodyomic, genetic, and genomic data.
* DER = fitSNP differential expression ratio.